Renaissance Technologies LLC Has $306,000 Stake in Liquidia Corporation $LQDA

Renaissance Technologies LLC reduced its stake in shares of Liquidia Corporation (NASDAQ:LQDA) by 96.1% during the 1st quarter, Holdings Channel.com reports. The firm owned 8,100 shares of the company’s stock after selling 198,753 shares during the quarter. Renaissance Technologies LLC’s holdings in Liquidia were worth $306,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Northwestern Mutual Wealth Management Co. acquired a new position in Liquidia during the 4th quarter worth $25,000. NewEdge Advisors LLC acquired a new stake in shares of Liquidia in the 2nd quarter valued at $25,000. Covestor Ltd increased its stake in shares of Liquidia by 41.9% in the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock valued at $42,000 after buying an additional 359 shares during the period. Tower Research Capital LLC TRC raised its position in shares of Liquidia by 281.2% during the second quarter. Tower Research Capital LLC TRC now owns 6,679 shares of the company’s stock worth $83,000 after acquiring an additional 4,927 shares during the last quarter. Finally, Hurley Capital LLC lifted its stake in shares of Liquidia by 140.7% during the fourth quarter. Hurley Capital LLC now owns 5,200 shares of the company’s stock valued at $179,000 after acquiring an additional 3,040 shares during the period. Institutional investors and hedge funds own 64.54% of the company’s stock.

Insider Transactions at Liquidia

In other news, Director Stephen M. Bloch sold 242,269 shares of the company’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $70.43, for a total value of $17,063,005.67. Following the completion of the sale, the director directly owned 1,176,184 shares of the company’s stock, valued at $82,838,639.12. This represents a 17.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Paul B. Manning sold 200,000 shares of the stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $63.91, for a total transaction of $12,782,000.00. Following the completion of the sale, the director owned 716,311 shares in the company, valued at $45,779,436.01. This represents a 21.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 1,731,861 shares of company stock worth $121,514,862. Company insiders own 25.60% of the company’s stock.

Liquidia Stock Performance

LQDA stock opened at $74.33 on Wednesday. Liquidia Corporation has a twelve month low of $21.15 and a twelve month high of $93.61. The company has a quick ratio of 2.12, a current ratio of 2.31 and a debt-to-equity ratio of 0.63. The company has a market cap of $6.65 billion, a P/E ratio of 54.26 and a beta of 0.58. The business’s fifty day moving average is $79.15 and its 200-day moving average is $55.70.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings data on Wednesday, August 12th. The company reported $0.74 EPS for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). The company had revenue of $171.68 million for the quarter, compared to analyst estimates of $168.48 million. Liquidia had a return on equity of 149.65% and a net margin of 30.74%.The firm’s revenue for the quarter was up 1842.1% on a year-over-year basis. During the same period last year, the firm earned ($0.49) earnings per share. Equities research analysts forecast that Liquidia Corporation will post 2.57 EPS for the current year.

Analyst Ratings Changes

Several research firms recently issued reports on LQDA. Zacks Research cut Liquidia from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 13th. Piper Sandler set a $129.00 price objective on Liquidia in a report on Friday, July 24th. Jefferies Financial Group restated a “buy” rating and set a $60.00 target price on shares of Liquidia in a research report on Monday, May 11th. HC Wainwright set a $36.00 target price on shares of Liquidia in a research note on Friday, July 24th. Finally, Raymond James Financial reiterated a “strong-buy” rating and set a $106.00 price target on shares of Liquidia in a research report on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Liquidia presently has an average rating of “Hold” and a consensus price target of $98.08.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).